Pancreatic Cancer
Conditions
Keywords
oncology, pancrease
Brief summary
Gemcitabine is considered one of the standard drugs for advanced pancreatic cancer and is approved by the FDA to treat it. Cabozantinib is a new drug that has demonstrated effectiveness against pancreatic cancer in laboratory experiments, especially when given with gemcitabine. Initial studies with cabozantinib in pancreatic cancer have shown some activity against the disease. The purpose of this study is to determine the safest and highest dose of cabozantinib that can be given together with standard doses of gemcitabine in patients with pancreatic cancer. This study will determine the safety and tolerability of this two drug combination.
Detailed description
Preclinical work at the University of Michigan has demonstrated that inhibition of c-Met with cabozantinib prevented the development of metastatic disease in an intra-cardiac injection model in NOD/SCID mice. Additionally, the combination of cabozantinib and gemcitabine demonstrated improved tumor control compared to either agent alone in a relevant orthotopic implantation mouse model. Combining gemcitabine with the c-Met inhibitor cabozantinib in advanced pancreatic cancer is a novel strategy that takes advantage of an established cytotoxic agent with one that targets a pathway known to be important for the growth, dissemination, and resistance of this disease.
Interventions
DRUGCABOZANTINIB
Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
DRUGgemcitabine
Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
Sponsors
University of Michigan Rogel Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. pathologically confirmed pancreatic carcinoma. 2. locally advanced unresectable disease, metastatic disease, or recurrent disease following surgical therapy. 3. ≥ 18 years old. 4. Life expectancy of greater than 12 weeks. 5. ECOG performance status ≤1 (Karnofsky ≥70%) (See Appendix A). 6. adequate organ and marrow function as follows: 7. capable of understanding and complying with the protocol requirements and has signed the informed consent document. 8. use medically accepted barrier methods of contraception 9. women of childbearing potential must have a negative pregnancy test at screening.
Exclusion criteria
1. neuroendocrine tumors of the pancreas. 2. more than 1 prior systemic treatment regimen for pancreatic cancer. may have received prior neoadjuvant or adjuvant therapy, including gemcitabine, provided 6 months have elapsed from completion of that treatment and the start of study therapy. 3. Previous gemcitabine therapy for advanced pancreatic cancer. Patients who have had chemotherapy within 4 weeks, nitrosoureas/mitomycin C within 6 weeks, or monoclonal antibody within 6 weeks prior to planned initiation of study treatment. 4. prior treatment with a small molecule kinase inhibitor or a hormonal therapy within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment. 5. have received an investigational agent within 28 days of the first dose of study treatment or 5 half-lives of the compound or active metabolite, whichever is longer. 6. have received radiation therapy within 14 days of study treatment. 7. have not recovered from toxicity due to all prior therapies (i.e., return to pretherapy baseline or to CTCAE Grade 0 or 1) except alopecia and non-clinically significant AEs. 8. known brain metastases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose | 5 weeks | The MTD is defined at the highest dose level at which ≤25% of patients experience a dose-limiting toxicity (DLT). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Median Progression-free Survival (PFS) | day-7 of cycle 1 until 30 days post treatment | Progression-free survival (PFS, a secondary endpoint) will be calculated from day-7 of cycle 1 of study treatment, until documented disease progression or death. Patients removed from treatment for progression or other reasons will be followed for 30 days after their last dose. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cabozantinib With Gemcitabine Patients received daily oral cabozantinib, at 20mg or 40mg, administered days -7 until disease progression, intolerable adverse event(s) or patient choice AND Gemcitabine at 800mg/m\^2 or 1000mg/m\^2 administered intravenously on days 1, 8, and 15 every 28 days. | 12 |
| Total | 12 |
Baseline characteristics
| Characteristic | Cabozantinib With Gemcitabine |
|---|---|
| Age, Continuous | 60.5 years |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 1 / 12 |
| other Total, other adverse events | 11 / 12 |
| serious Total, serious adverse events | 4 / 12 |
Outcome results
Primary
Maximum Tolerated Dose
The MTD is defined at the highest dose level at which ≤25% of patients experience a dose-limiting toxicity (DLT).
Time frame: 5 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cabozantinib With Gemcitabine | Maximum Tolerated Dose | NA mg |
Secondary
Median Progression-free Survival (PFS)
Progression-free survival (PFS, a secondary endpoint) will be calculated from day-7 of cycle 1 of study treatment, until documented disease progression or death. Patients removed from treatment for progression or other reasons will be followed for 30 days after their last dose.
Time frame: day-7 of cycle 1 until 30 days post treatment
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cabozantinib With Gemcitabine | Median Progression-free Survival (PFS) | 4.7 months |